Raloxifene preserves BMD in early postmenopausal women

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1276, 2001-01, pp. : 16-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

QOL effect of raloxifene, HRT in postmenopausal women

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 384, 2002-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene

By Ko Seung Sang   Jordan V Craig  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 4, 2011-03 ,pp. : 657-674

Informa Healthcare

Access to resources Recommend Favorite

Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene

By  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 1081-1081

Informa Healthcare

Access to resources Recommend Favorite

The STAR Trial: Evidence for Raloxifene as a Breast Cancer Risk Reduction Agent for Postmenopausal Women

By Bevers Therese B.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 5, Iss. 8, 2007-09 ,pp. : 817-822

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

HRT more cost effective than raloxifene in postmenopausal women?

By  

Inpharma, Vol. 1, Iss. 1320, 2002-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite